Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group.

Papageorgiou SG, Kotsianidis I, Kontos CK, Symeonidis A, Galanopoulos A, Hatzimichael E, Poulakidas E, Diamantopoulos P, Vassilakopoulos TP, Zikos P, Papadaki H, Bouronikou E, Panayiotidis P, Viniou NA, Pappa V.

Leuk Res. 2018 Aug;71:55-59. doi: 10.1016/j.leukres.2018.07.004. Epub 2018 Jul 7. No abstract available.

PMID:
30007218
2.

Efficacy-safety of Facilitated Subcutaneous Immunoglobulin in Immunodeficiency Due to Hematological Malignancies. A Single-Center Retrospective Analysis.

Dimou M, Iliakis T, Maltezas D, Bitsani A, Kalyva S, Koudouna A, Kotsanti S, Petsa P, Papaioannou P, Kyrtsonis MC, Panayiotidis P.

Anticancer Res. 2018 Jul;38(7):4187-4191. doi: 10.21873/anticanres.12712.

PMID:
29970548
3.

Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis.

Tsirigotis P, Vassilakopoulos T, Batsis I, Bousiou Z, Gkirkas K, Sakellari I, Kaloyannidis P, Roussou P, Pangalis GA, Moschogiannis M, Vassilopoulos G, Repousis P, Megalakaki A, Michalis E, Kalpadakis C, Papadaki HA, Kotsianidis I, Hatzimichael E, Spyridonidis A, Anargyrou K, Poulakidas E, Giannoullia P, Apostolidis I, Stamouli M, Konstantopoulos K, Pappa V, Panayiotidis P, Harhalakis N, Anagnostopoulos A, Angelopoulou M.

Hematol Oncol. 2018 Jun 8. doi: 10.1002/hon.2521. [Epub ahead of print]

PMID:
29882363
4.

Primary Hepatic Burkitt Lymphoma in a Kidney Transplant Recipient.

Lionaki S, Tsakonas E, Androulaki A, Liapis G, Panayiotidis P, Zavos G, Boletis JN.

Case Rep Nephrol. 2018 May 13;2018:7425785. doi: 10.1155/2018/7425785. eCollection 2018.

5.

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.

Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Strömberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machová Poláková K, Müller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX; EURO-SKI investigators.

Lancet Oncol. 2018 Jun;19(6):747-757. doi: 10.1016/S1470-2045(18)30192-X. Epub 2018 May 4.

PMID:
29735299
6.

The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group.

Papageorgiou SG, Vasilatou D, Kontos CK, Kotsianidis I, Symeonidis A, Galanopoulos AG, Hatzimichael E, Megalakaki A, Poulakidas E, Diamantopoulos P, Vassilakopoulos TP, Zikos P, Papadaki H, Mparmparousi D, Bouronikou E, Panayiotidis P, Viniou NA, Pappa V.

Am J Hematol. 2018 Jul;93(7):895-901. doi: 10.1002/ajh.25111. Epub 2018 May 16.

PMID:
29659040
7.

Study of bone metabolism and angiogenesis in patients undergoing high-dose chemotherapy/autologous hematopoietic stem cell transplantation.

Boutsikas G, Terpos E, Papatheodorou A, Tsirkinidis P, Tsirigotis P, Meletiou A, Lalou E, Telonis V, Zannou A, Kanellopoulos A, Galani Z, Stefanou A, Tsaftaridis P, Viniou NA, Panayiotidis P, Kyrtsonis MC, Meletis J, Vassilakopoulos TP, Angelopoulou MK.

Eur J Haematol. 2018 Feb;100(2):131-139. doi: 10.1111/ejh.12990. Epub 2017 Dec 4.

PMID:
29105864
8.

The Significance of PET/CT in the Initial Staging of Hodgkin Lymphoma: Experience Outside Clinical Trials.

Angelopoulou MK, Mosa E, Pangalis GA, Rondogianni P, Chatziioannou S, Prassopoulos V, Moschogianni M, Tsirkinidis P, Asimakopoulos JV, Konstantinou I, Tsourouflis G, Sachanas S, Yiakoumis X, Boutsikas G, Arapaki M, Gainaru G, Kyrtsonis MC, Siakantaris MP, Datseris I, Panayiotidis P, Konstantopoulos K, Vassilakopoulos TP.

Anticancer Res. 2017 Oct;37(10):5727-5736.

PMID:
28982893
9.

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

Dreyling M, Santoro A, Mollica L, Leppä S, Follows GA, Lenz G, Kim WS, Nagler A, Panayiotidis P, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Giurescu M, Cupit L, Liu L, Köchert K, Seidel H, Peña C, Yin S, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL.

J Clin Oncol. 2017 Dec 10;35(35):3898-3905. doi: 10.1200/JCO.2017.75.4648. Epub 2017 Oct 4.

PMID:
28976790
10.

High-grade B-cell lymphoma of the peritoneum as a result of transformation of a CD5-negative monoclonal B lymphocytosis population in a patient with myelodysplastic syndrome treated with 5-azacytidine.

Dimou M, Roumelioti M, Dimitrakopoulou A, Bitsani C, Kotsanti S, Petsa P, Papaioannou P, Kyrtsonis MC, Panayiotidis P.

Leuk Lymphoma. 2018 May;59(5):1264-1267. doi: 10.1080/10428194.2017.1375108. Epub 2017 Sep 13. No abstract available.

PMID:
28901815
11.

Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization.

Tsirkinidis P, Terpos E, Boutsikas G, Papatheodorou A, Anargyrou K, Lalou E, Dimitrakopoulou A, Kalpadakis C, Konstantopoulos K, Siakantaris M, Panayiotidis P, Pangalis G, Kyrtsonis MC, Vassilakopoulos T, Angelopoulou MK.

J Bone Miner Metab. 2018 Jul;36(4):399-409. doi: 10.1007/s00774-017-0853-4. Epub 2017 Jun 28.

PMID:
28660376
12.

Thioredoxin-1, chemokine (C-X-C motif) ligand-9 and interferon-γ expression in the neoplastic cells and macrophages of Hodgkin lymphoma: clinicopathologic correlations and potential prognostic implications.

P Vassilakopoulos T, Levidou G, Milionis V, Hartmann S, Lakiotaki E, Sepsa A, Thymara I, Ntailiani P, Spanou K, K Angelopoulou M, P Siakantaris M, Moschogiannis M, A Pangalis G, Panayiotidis P, Konstantopoulos K, Patsouris E, Hansmann ML, Korkolopoulou P.

Leuk Lymphoma. 2017 Sep;58(9):1-13. doi: 10.1080/10428194.2017.1289520. Epub 2017 Jun 2.

PMID:
28571489
13.

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience.

Angelopoulou MK, Vassilakopoulos TP, Batsis I, Sakellari I, Gkirkas K, Pappa V, Giannoulia P, Apostolidis I, Apostolopoulos C, Roussou P, Panayiotidis P, Dimou M, Kyrtsonis MC, Palassopoulou M, Vassilopoulos G, Moschogiannis M, Kalpadakis C, Margaritis D, Spyridonidis A, Michalis E, Anargyrou K, Repousis P, Hatzimichael E, Bousiou Z, Poulakidas E, Grentzelias D, Harhalakis N, Pangalis GA, Anagnostopoulos A, Tsirigotis P.

Hematol Oncol. 2018 Feb;36(1):174-181. doi: 10.1002/hon.2383. Epub 2017 Feb 20.

14.

Detection of L265P MYD-88 mutation in a series of clonal B-cell lymphocytosis of marginal zone origin (CBL-MZ).

Kalpadakis C, Pangalis GA, Vassilakopoulos TP, Roumelioti M, Sachanas S, Korkolopoulou P, Koulieris E, Moschogiannis M, Yiakoumis X, Tsirkinidis P, Pontikoglou C, Rondoyianni D, Papadaki HA, Panayiotidis P, Angelopoulou MK.

Hematol Oncol. 2017 Dec;35(4):542-547. doi: 10.1002/hon.2361. Epub 2016 Oct 13.

PMID:
27734522
15.

Extramedullary sudden blast crisis in chronic-phase chronic myeloid leukemia during first-line treatment with nilotinib.

Angelopoulou MK, Asimakopoulos JV, Galani Z, Levidou G, Roumelioti M, Vassilakopoulos TP, Korkolopoulou P, Panayiotidis P.

Blood Cancer J. 2016 Aug 26;6(8):e461. doi: 10.1038/bcj.2016.66. No abstract available.

16.

Response to 'PET after response to R-CHOP in primary mediastinal large B-cell lymphoma'.

Vassilakopoulos TP, Papageorgiou S, Pangalis GA, Chatziioannou S, Angelopoulou MK, Panayiotidis P, Konstantopoulos K, Rondogianni P.

Leukemia. 2016 Aug;30(8):1800-1. doi: 10.1038/leu.2016.109. Epub 2016 Jun 3. No abstract available.

PMID:
27256701
17.

A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL.

Flinn IW, Panayiotidis P, Afanasyev B, Janssens A, Grosicki S, Homenda W, Smolej L, Kuliczkowski K, Doubek M, Domnikova N, West SL, Chang CN, Barker AM, Gupta IV, Wright OJ, Offner F.

Am J Hematol. 2016 Sep;91(9):900-6. doi: 10.1002/ajh.24430. Epub 2016 Jul 3.

18.

Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens.

Vassilakopoulos TP, Dimopoulou MN, Angelopoulou MK, Petevi K, Pangalis GA, Moschogiannis M, Dimou M, Boutsikas G, Kanellopoulos A, Gainaru G, Plata E, Flevari P, Koutsi K, Papageorgiou L, Telonis V, Tsaftaridis P, Sachanas S, Yiakoumis X, Tsirkinidis P, Viniou NA, Siakantaris MP, Variami E, Kyrtsonis MC, Meletis J, Panayiotidis P, Konstantopoulos K.

Oncologist. 2016 Mar;21(3):343-53. doi: 10.1634/theoncologist.2015-0251. Epub 2016 Feb 26.

19.

Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcome.

Lakiotaki E, Levidou G, Angelopoulou MK, Adamopoulos C, Pangalis G, Rassidakis G, Vassilakopoulos T, Gainaru G, Flevari P, Sachanas S, Saetta AA, Sepsa A, Moschogiannis M, Kalpadakis C, Tsesmetzis N, Milionis V, Chatziandreou I, Thymara I, Panayiotidis P, Dimopoulou M, Plata E, Konstantopoulos K, Patsouris E, Piperi C, Korkolopoulou P.

Sci Rep. 2016 Feb 19;6:21252. doi: 10.1038/srep21252.

20.

Expression, prognostic significance and mutational analysis of protein tyrosine phosphatase SHP-1 in chronic myeloid leukemia.

Papadopoulou V, Kontandreopoulou E, Panayiotidis P, Roumelioti M, Angelopoulou M, Kyriazopoulou L, Diamantopoulos PT, Vaiopoulos G, Variami E, Kotsianidis I, Athina Viniou N.

Leuk Lymphoma. 2016 May;57(5):1182-8. doi: 10.3109/10428194.2015.1090573. Epub 2015 Dec 23.

PMID:
26373709
21.

The role of magnetic resonance imaging in the evaluation of transfusional iron overload in myelodysplastic syndromes.

Petrou E, Mavrogeni S, Karali V, Kolovou G, Kyrtsonis MC, Sfikakis PP, Panayiotidis P.

Rev Bras Hematol Hemoter. 2015 Jul-Aug;37(4):252-8. doi: 10.1016/j.bjhh.2015.03.014. Epub 2015 May 19.

22.

PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy.

Vassilakopoulos TP, Pangalis GA, Chatziioannou S, Papageorgiou S, Angelopoulou MK, Galani Z, Kourti G, Prassopoulos V, Leonidopoulou T, Terpos E, Dimopoulou MN, Sachanas S, Kalpadakis C, Konstantinidou P, Boutsis D, Stefanoudaki E, Kyriazopoulou L, Siakantaris MP, Kyrtsonis MC, Variami E, Kotsianidis I, Symeonidis A, Michali E, Katodritou E, Kokkini G, Tsatalas C, Papadaki H, Dimopoulos MA, Sotiropoulos V, Pappa V, Karmiris T, Meletis J, Apostolidis J, Datseris I, Panayiotidis P, Konstantopoulos K, Roussou P, Rondogianni P.

Leukemia. 2016 Jan;30(1):238-42. doi: 10.1038/leu.2015.120. Epub 2015 May 14. No abstract available.

PMID:
25971363
23.

Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) with concurrent high grade component at diagnosis: clinico-pathologic features and treatment strategy.

Sachanas S, Pangalis GA, Kalpadakis C, Levidou G, Yiakoumis X, Moschogiannis M, Kyrtsonis MC, Vassilakopoulos TP, Tsirkinidis P, Siakantaris M, Spiliadi C, Karagianni E, Korkolopoulou P, Rontogianni D, Papadaki H, Panayiotidis P, Angelopoulou M.

Leuk Lymphoma. 2015;56(11):3230-2. doi: 10.3109/10428194.2015.1034698. Epub 2015 May 12. No abstract available.

PMID:
25827212
24.

New insights into malignant B-cell disorders.

Kyrtsonis MC, Shimizu K, Panayiotidis P, Pangalis GA.

Biomed Res Int. 2015;2015:128084. doi: 10.1155/2015/128084. Epub 2015 Jan 28. No abstract available.

25.

Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.

Moreno C, Montillo M, Panayiotidis P, Dimou M, Bloor A, Dupuis J, Schuh A, Norin S, Geisler C, Hillmen P, Doubek M, Trněný M, Obrtlikova P, Laurenti L, Stilgenbauer S, Smolej L, Ghia P, Cymbalista F, Jaeger U, Stamatopoulos K, Stavroyianni N, Carrington P, Zouabi H, Leblond V, Gomez-Garcia JC, Rubio M, Marasca R, Musuraca G, Rigacci L, Farina L, Paolini R, Pospisilova S, Kimby E, Bradley C, Montserrat E.

Haematologica. 2015 Apr;100(4):511-6. doi: 10.3324/haematol.2014.118158. Epub 2015 Jan 16.

26.

Novel oral anticoagulants in the management of polycythemia vera and essential thrombocythemia.

Karali V, Panayiotidis P.

Cardiovasc Hematol Agents Med Chem. 2014;12(1):26-8. Review.

PMID:
25470150
27.

New insights into monoclonal B-cell lymphocytosis.

Kalpadakis C, Pangalis GA, Sachanas S, Vassilakopoulos TP, Kyriakaki S, Korkolopoulou P, Koulieris E, Moschogiannis M, Yiakoumis X, Tsirkinidis P, Kyrtsonis MC, Levidou G, Papadaki HA, Panayiotidis P, Angelopoulou MK.

Biomed Res Int. 2014;2014:258917. doi: 10.1155/2014/258917. Epub 2014 Sep 11. Review.

28.

Clonotypic analysis of immunoglobulin heavy chain sequences in patients with Waldenström's macroglobulinemia: correlation with MYD88 L265P somatic mutation status, clinical features, and outcome.

Petrikkos L, Kyrtsonis MC, Roumelioti M, Georgiou G, Efthymiou A, Tzenou T, Panayiotidis P.

Biomed Res Int. 2014;2014:809103. doi: 10.1155/2014/809103. Epub 2014 Aug 14.

29.

Cadherin-11 mRNA transcripts are frequently found in rheumatoid arthritis peripheral blood and correlate with established polyarthritis.

Sfikakis PP, Christopoulos PF, Vaiopoulos AG, Fragiadaki K, Katsiari C, Kapsimali V, Lallas G, Panayiotidis P, Korkolopoulou P, Koutsilieris M.

Clin Immunol. 2014 Nov;155(1):33-41. doi: 10.1016/j.clim.2014.08.008. Epub 2014 Aug 27.

PMID:
25173800
30.

Serum soluble TACI, a BLyS receptor, is a powerful prognostic marker of outcome in chronic lymphocytic leukemia.

Kyrtsonis MC, Sarris K, Koulieris E, Maltezas D, Nikolaou E, Angelopoulou MK, Bartzis V, Tzenou T, Dimou M, Siakandaris MP, Viniou NA, Sachanas S, Kalpadakis C, Sfikakis PP, Pangalis GA, Panayiotidis P.

Biomed Res Int. 2014;2014:159632. doi: 10.1155/2014/159632. Epub 2014 Aug 6.

31.

The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma.

Atsaves V, Lekakis L, Drakos E, Leventaki V, Ghaderi M, Baltatzis GE, Chioureas D, Jones D, Feretzaki M, Liakou C, Panayiotidis P, Gorgoulis V, Patsouris E, Medeiros LJ, Claret FX, Rassidakis GZ.

Br J Haematol. 2014 Nov;167(4):514-23. doi: 10.1111/bjh.13079. Epub 2014 Aug 22.

PMID:
25145835
32.

Favorable outcome in non-Hodgkin lymphoma of the maxillary sinus treated with R-CHOP.

Doumas S, Sakkas L, Panayiotidis P, Wozniak G, Vlychou M, Vassilopoulos G.

Arch Med Sci. 2014 May 12;10(2):406-9. doi: 10.5114/aoms.2013.34986. Epub 2013 Apr 30. No abstract available.

33.

Immunohistochemical analysis of IL-6, IL-8/CXCR2 axis,  Tyr p-STAT-3, and SOCS-3 in lymph nodes from patients with chronic lymphocytic leukemia: correlation between microvascular characteristics and prognostic significance.

Levidou G, Sachanas S, Pangalis GA, Kalpadakis C, Yiakoumis X, Moschogiannis M, Sepsa A, Lakiotaki E, Milionis V, Kyrtsonis MC, Vassilakopoulos TP, Tsirkinidis P, Kontopidou F, Kokoris S, Siakantaris M, Angelopoulou M, Papadaki H, Kavantzas N, Panayiotidis P, Patsouris E, Korkolopoulou P.

Biomed Res Int. 2014;2014:251479. doi: 10.1155/2014/251479. Epub 2014 May 5.

34.

Expression of three different ATP-binding cassette transporters and correlation to chemoresistance in acute myeloid leukemia.

Palaiologou D, Panayiotidis P, Papanikolaou G, Georgiou G, Boutsikas G, Hatzinicolaou SL, Pangalis GA, Sakellaropoulos N, Vassilakopoulos TP, Angelopoulou MK.

Int J Lab Hematol. 2015 Feb;37(1):e7-e10. doi: 10.1111/ijlh.12249. Epub 2014 May 9. No abstract available.

PMID:
24809224
35.

Tyrosine kinase inhibitors and interferon.

Dimou M, Panayiotidis P.

Mediterr J Hematol Infect Dis. 2014 Jan 2;6(1):e2014006. doi: 10.4084/MJHID.2014.006. eCollection 2014 Jan 2. Review.

36.

Prognostic significance of serum free light chains in chronic lymphocytic leukemia.

Sarris K, Maltezas D, Koulieris E, Bartzis V, Tzenou T, Sachanas S, Nikolaou E, Efthymiou A, Bitsani K, Dimou M, Vassilakopoulos TP, Siakantaris M, Angelopoulou MK, Kontopidou F, Tsaftaridis P, Kafasi N, Pangalis GA, Panayiotidis PP, Harding S, Kyrtsonis MC.

Adv Hematol. 2013;2013:359071. doi: 10.1155/2013/359071. Epub 2013 Oct 29.

37.

Operationalizing sustainability in urban coastal systems: a system dynamics analysis.

Mavrommati G, Bithas K, Panayiotidis P.

Water Res. 2013 Dec 15;47(20):7235-50. doi: 10.1016/j.watres.2013.10.041. Epub 2013 Oct 23.

PMID:
24200010
38.

Cessation of tyrosine kinase inhibitors in patients with chronic-phase chronic myelogenous leukemia following durable complete molecular response: a single center facing the dilemma.

Iliakis T, Papadopoulou V, Diamantopoulos PT, Panayiotidis P, Zervakis K, Giannakopoulou N, Tilimidos G, Angelopoulou M, Siakantaris MP, Pangalis G, Mantzourani M, Variami E, Viniou NA.

Anticancer Res. 2013 Aug;33(8):3509-14.

PMID:
23898127
39.

A prospective, cohort, multicentre study of candidaemia in hospitalized adult patients with haematological malignancies.

Gamaletsou MN, Walsh TJ, Zaoutis T, Pagoni M, Kotsopoulou M, Voulgarelis M, Panayiotidis P, Vassilakopoulos T, Angelopoulou MK, Marangos M, Spyridonidis A, Kofteridis D, Pouli A, Sotiropoulos D, Matsouka P, Argyropoulou A, Perloretzou S, Leckerman K, Manaka A, Oikonomopoulos P, Daikos G, Petrikkos G, Sipsas NV.

Clin Microbiol Infect. 2014 Jan;20(1):O50-7. doi: 10.1111/1469-0691.12312. Epub 2013 Jul 24.

40.

Apoptotic and proliferative characteristics of proliferation centers in lymph node sections of patients with chronic lymphocytic leukemia.

Sachanas S, Levidou G, Angelopoulou MK, Moschogiannis M, Yiakoumis X, Kalpadakis C, Vassilakopoulos TP, Kontopidou F, Tsirkinidis P, Dimitrakopoulou A, Kokoris S, Dimitriadou E, Kyrtsonis MC, Panayiotidis P, Papadaki H, Patsouris E, Korkolopoulou P, Pangalis GA.

Leuk Lymphoma. 2014 Mar;55(3):571-82. doi: 10.3109/10428194.2013.806802. Epub 2013 Jun 24.

PMID:
23697878
41.

Ratio of involved/uninvolved immunoglobulin quantification by Hevylite™ assay: clinical and prognostic impact in multiple myeloma.

Koulieris E, Panayiotidis P, Harding SJ, Kafasi N, Maltezas D, Bartzis V, Tzenou T, Dimou M, Georgiou G, Mirbahai L, Bradwell AR, Kyrtsonis MC.

Exp Hematol Oncol. 2012 Apr 23;1(1):9. doi: 10.1186/2162-3619-1-9.

42.

Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents.

Maltezas D, Dimopoulos MA, Katodritou I, Repousis P, Pouli A, Terpos E, Panayiotidis P, Delimpasi S, Michalis E, Anargyrou K, Gavriatopoulou M, Stefanoudaki A, Tzenou T, Koulieris E, Sachanas S, Dimou M, Vassilakopoulos TP, Angelopoulou MK, Pangalis GA, Kyrtsonis MC.

Hematol Oncol. 2013 Jun;31(2):96-102. doi: 10.1002/hon.2026. Epub 2012 Sep 7. Erratum in: Hematol Oncol. 2013 Spe;31(3):168.

PMID:
22961993
43.

Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.

Papageorgiou SG, Diamantopoulos P, Levidou G, Angelopoulou MK, Economopoulou P, Efthimiou A, Constantinou N, Katsigiannis A, Korkolopoulou P, Pappa V, Economopoulou C, Georgiou G, Dimou M, Tsirigotis P, Kyrtsonis MC, Kotsianidis I, Kalpadakis C, Dimopoulos MA, Beris P, Meletis J, Pangalis GA, Dervenoulas J, Panayiotidis P, Vassilakopoulos TP.

Hematol Oncol. 2013 Mar;31(1):10-7. doi: 10.1002/hon.2012. Epub 2012 May 18.

PMID:
22610484
44.

Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care.

Vassilakopoulos TP, Pangalis GA, Katsigiannis A, Papageorgiou SG, Constantinou N, Terpos E, Zorbala A, Vrakidou E, Repoussis P, Poziopoulos C, Galani Z, Dimopoulou MN, Kokoris SI, Sachanas S, Kalpadakis C, Dimitriadou EM, Siakantaris MP, Kyrtsonis MC, Dervenoulas J, Dimopoulos MA, Meletis J, Roussou P, Panayiotidis P, Beris P, Angelopoulou MK.

Oncologist. 2012;17(2):239-49. doi: 10.1634/theoncologist.2011-0275. Epub 2012 Jan 26.

45.

Autoimmune hemolytic anemia and autoimmune thrombocytopenia at diagnosis and during follow-up of Hodgkin lymphoma.

Dimou M, Angelopoulou MK, Pangalis GA, Georgiou G, Kalpadakis C, Pappi V, Tsopra O, Koutsoukos K, Zografos E, Boutsikas G, Moschogianni M, Vardounioti I, Petevi K, Karali V, Kanellopoulos A, Ntalageorgos T, Yiakoumis X, Bartzis V, Bitsani A, Pessach E, Efthimiou A, Korkolopoulou P, Rassidakis G, Kyrtsonis MC, Patsouris E, Meletis J, Panayiotidis P, Vassilakopoulos TP.

Leuk Lymphoma. 2012 Aug;53(8):1481-7. doi: 10.3109/10428194.2012.660628. Epub 2012 Apr 2.

PMID:
22280533
46.

Development of acute myeloid leukemia with NPM1 mutation, in Ph-negative clone, during treatment of CML with imatinib.

Georgiou G, Efthymiou A, Vardounioti I, Boutsikas G, Angelopoulou MK, Vassilakopoulos TP, Kyrtsonis MC, Plata E, Tofas P, Bitsani A, Bartzi V, Pessach I, Dimou M, Panayiotidis P.

Leukemia. 2012 Apr;26(4):824-6. doi: 10.1038/leu.2011.280. Epub 2011 Oct 11. No abstract available.

PMID:
21986839
47.

Immunohistochemical expression and prognostic significance of CCND3, MCM2 and MCM7 in Hodgkin lymhoma.

Marnerides A, Vassilakopoulos TP, Boltetsou E, Levidou G, Angelopoulou MK, Thymara I, Kyrtsonis MC, Pappi V, Tsopra O, Panayiotidis P, Pangalis GA, Beris P, Patsouris E, Korkolopoulou P.

Anticancer Res. 2011 Oct;31(10):3585-94.

PMID:
21965782
48.

CD20 expression in angioimmunoblastic T cell lymphoma.

Foukas PG, Kefala M, Papageorgiou S, Tsirigotis P, Panayiotidis P, Korkolopoulou P, Spathis A, Dervenoulas J, Patsouris E, Karakitsos P, Panayiotides IG.

Leuk Lymphoma. 2012 Feb;53(2):345-7. doi: 10.3109/10428194.2011.602768. Epub 2011 Nov 15. No abstract available.

PMID:
21919822
49.

Novel M-component based biomarkers in Waldenström's macroglobulinemia.

Leleu X, Koulieris E, Maltezas D, Itzykson R, Xie W, Manier S, Dulery R, Boyle E, Gauthier J, Poulain S, Tatiana T, Panayiotidis P, Bradwell AR, Harding S, Leblond V, Kyrtsonis MC, Ghobrial IM.

Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):164-7. doi: 10.3816/CLML.2011.n.039.

PMID:
21454223
50.

CD138 expression helps distinguishing Waldenström's macroglobulinemia (WM) from splenic marginal zone lymphoma (SMZL).

Kyrtsonis MC, Levidou G, Korkolopoulou P, Koulieris E, Bartzi V, Maltezas D, Pangalis GA, Kalpadakis C, Dimou M, Georgiou G, Vassilakopoulos TP, Angelopoulou MK, Salpeas V, Tsaftaridis P, Patsouris E, Panayiotidis P, Tzenou TK.

Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):99-102. doi: 10.3816/CLML.2011.n.019.

PMID:
21454203

Supplemental Content

Loading ...
Support Center